Stay updated on Brentuximab/Nivolumab Combo in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Brentuximab/Nivolumab Combo in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Brentuximab/Nivolumab Combo in Hodgkin Lymphoma Clinical Trial page
- Check7 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference1%
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference1%
- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check43 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, and API users can provide input before this change. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check72 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check86 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study information regarding the safety and efficacy of brentuximab vedotin combined with nivolumab for Hodgkin lymphoma, while adding a new version revision and collaborators.SummaryDifference15%
Stay in the know with updates to Brentuximab/Nivolumab Combo in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Brentuximab/Nivolumab Combo in Hodgkin Lymphoma Clinical Trial page.